ALVOGEN
GenericsALVOGEN is a generic drug manufacturer focused on Metabolic, Oncology, Dermatology. Key products include BONSITY.
ALVOGEN at a Glance
- Strong track record with 88% execution quality across 19 trials
- Fast trial execution (5 months median completion)
ALVOGEN's Key Drugs
ALVOGEN's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BONSITY, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.
ALVOGEN's Recent FDA Approvals
ALVOGEN secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ALVOGEN's Therapeutic Areas
ALVOGEN's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALVOGEN's Top Competitors
ALVOGEN's closest competitors by therapeutic-area and drug-target overlap include Baxter, Takeda, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALVOGEN Pipeline Snapshot
ALVOGEN has 4 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/5 completed
- • Speed: 5 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1971-06-30
- Latest
- 2026-06-18
- Applications
- 54
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges